Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
Homo sapiens tumor protein p53 (TP53), transcript variant 1
Synonyms:
BCC7; LFS1; P53; TRP53
Immunogen
A synthetic peptide corresponding to N-terminal residues human p53 was used as immunogen. The antibody should recognize human wild-type and mutant p53.
Buffer
50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
p53 acts as both a tumor-suppressor and transcription factor that, upon activation by DNA damage and other cellular stress signals, leads to the transcription of genes triggering cell-cycle arrest, apoptosis, and DNA repair (1,2). The gene for the nuclear phosphoprotein p53 is the most commonly mutated gene yet identified in human cancers (3). p53 is frequently mutated or inactivated in about 60% of cancers (4,5).
Related Pathway
Apoptosis
Cell cycle
Delta-Notch Signaling Pathway
MAPK signaling pathway
Senescence and Autophagy
TGF Beta Signaling Pathway
Wnt Signaling Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
(A) IHC analysis of paraffin-embedded human skin cancer, showing nuclear localization of p53, using anti-p53; (B)IHC analysis of paraffin-embedded human breast cancer, showing nuclear localization of p53, using anti-p53
Researchers who bought this antibody have also purchased:
